{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}],"title":"Multiple meyloma deaths"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Acute Myeloid Leukemia death"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Lung cancer death"},{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Heart attack death"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"Alive"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"number of patients alive or dead","groups":[{"description":"Patients receive clarithromycin orally (PO) twice daily and dexamethasone PO once a week. Treatment with clarithromycin and dexamethasone continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also receive lenalidomide PO once daily on days 1-14. Courses with lenalidomide repeat every 21 days in the absence of disease progression or unacceptable toxicity. Lenalidomide is taken 4 hours or more after last dose of daily clarithromycin.\n\nNOTE: \\*After one year of treatment, dexamethasone is tapered for an additional 4 weeks.\n\nClarithromycin: Given Orally (PO)\n\nDexamethasone: Given PO\n\nLenalidomide: Given PO","id":"OG000","title":"Treatment (Clarithromycin, Dexamethasone, Lenalidomide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"From date of transplant until the date of death from any cause, assessed up to 10.25 years","title":"Survival","type":"SECONDARY","unitOfMeasure":"Participants"}